Site Updates

Five additions to the interaction checker

Bortezomib, pertuzumab, thalidomide, trastuzumab and trastuzumab-emtansine are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications. 

• Bortezomib (Velcade®) is a proteasome inhibitor and is indicated for the treatment of multiple myeloma and mantle cell lymphoma.
• Pertuzumab (Perjeta®) is a monoclonal antibody and ...

Three drugs indicated for multiple myeloma have been added to the interaction checker

Elotuzumab, lenalidomide and panobinostat are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications. 

• Elotuzumab (Emplicti®) is a SLAMF7-directed antibody and is indicated for the treatment of multiple myeloma.
• Lenalidomide (Revlimid®) is an immunomodulatory agent and is indicated for the treatment of multiple mye...

Three additions to the interaction checker

Daratumumab, ixazomib and pomalidomide are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications. 

• Daratumumab (Darzalex®) is a CD38-directed antibody and is indicated for the treatment of multiple myeloma.
• Ixazomib (Ninlaro®) is a proteasome inhibitor and is indicated for the treatment of multiple myeloma. 

Seven new comedications

Seven new comedications have been added to the interaction checker and are listed below with their therapeutic classes.

• Ambrisentan - Hypertension/Heart Failure Agents
• Fosaprepitant - Gastrointestinal Agents (anti-emetics)
• Fosphenytoin - Anticonvulsants
• Nadroparin - Anti-coagulant, Anti-platelet and Fibrinolytic
• Taz...

Three cancer drugs have been added to the interaction checker

Acalabrutinib, blinatumomab and inotuzumab ozogamicin are now listed in the interaction checker as cancer drugs and interactions can be found for all the comedications.

• Acalabrutinib (Calquence®) is a Bruton’s tyrosine kinase inhibitor and is indicated for the treatment of mantle cell leukemia.
• Blinatumomab (Blincyto®) is a bispecific CD19-directed CD3 T-cell engager and is indic...

Three targeted therapies have been added to the interaction checker.

Avelumab, niraparib and tivozanib are now listed in the interaction checker as cancer drugs and interactions can be found for all the comedications.

• Avelumab (Bavencio®) is a monoclonal antibody and is indicated for the treatment of Merkel cell carcinoma.
• Niraparib (Zejula®) is a PARP inhibitor and is indicated for the treatment of epithelial ovarian, fallopian tube or prima...

Three cancer drugs have been added to the interaction checker

Capecitabine, cetuximab and panitumumab are now listed in the interaction checker as cancer drugs and interactions can be found for all the comedications. 

• Capecitabine (Xeloda®) is an antimetabolite and is indicated for the treatment of breast neoplasms, colonic neoplasms, colorectal neoplasms and stomach neoplasms. 
• Cetuximab (Erbitux®) is an EGFR inhibitor and is ind...

Two additions to the interaction checker

Ibrutinib and venetoclax are now listed in the interaction checker as cancer drugs and interactions can be found for all the comedications.

• Ibrutinib (Imbruvica®) is a Bruton’s tyrosine kinase inhibitor and is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic B-cell leukemia and Waldenström macroglobulinemia.
• Venetoclax (Venclyxto®, Venclexta®) is a BC...

Ofatumumab – now available on the interaction checker

Ofatumumab is now listed in the interaction checker as a cancer drug and interactions can be found for all the comedications. 

Ofatumumab (Arzerra®) is a monoclonal antibody and is indicated for the treatment of chronic lymphocytic B-cell leukemia. 

Four cancer drugs have been added to the interaction checker

Alemtuzumab, dabrafenib, obinutuzumab and trametinib have been added to the interaction checker as cancer drugs and interactions can be found for all the comedications.

• Alemtuzumab (Campath®, MabCampath®) is a monoclonal antibody and is indicated for the treatment of chronic lymphocytic B-cell leukemia.
• Dabrafenib (Tafinlar®, Rafinlar®) is a BRAF inhibitor and is indicated f...

Two additional drugs have been added to the interaction checker

Cobimetinib and vemurafenib are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications. 

• Cobimetinib (Cotellic®) is a MEK inhibitor and is indicated for the treatment of melanoma.
• Vemurafenib (Zelboraf®) is BRAF inhibitor and is indicated for the treatment of melanoma. 

Ipilimumab – the latest addition to the interaction checker

Ipilimumab is now listed in the interaction checker as a cancer drug and interactions can be found with all the comedications.

Ipilimumab (Yervoy®) is a monoclonal antibody and is indicated for the treatment of melanoma.

Pembrolizumab – now available on the interaction checker

Pembrolizumab is now listed in the interaction checker as a cancer drug and interactions can be found with all the comedications. 

Pembrolizumab (Keytruda®) is a monoclonal antibody and is indicated for the treatment of melanoma, non-small cell lung cancer and Hodgkin disease.

Brentuximab vedotin – now available on the interaction checker

Brentuximab vedotin is now listed in the interaction checker as a cancer drug and interactions can be found with all the comedications.

Brentuximab vedotin (Adcetris®) is an antibody-drug conjugate and is indicated for the treatment of Hodgkin disease and Non-Hodgkin lymphoma.  

Two additional drugs now available on the interaction checker

Idelalisib and rituximab are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications. 

• Idelalisib (Zydelig®) is a phosphoinositide 3-kinase inhibitor and is indicated for the treatment of chronic lymphocytic B-cell leukemia and non-Hodgkin lymphoma.
• Rituximab (MabThera®, Truxima®, Rituxan®) is a monoclonal antibody an...

Two hormonal therapies for prostatic neoplasms now available on the interaction checker

Abiraterone and enzalutamide are now listed in the interaction checker as cancer drugs and interactions can be found for all the comedications. 

• Abiraterone (Zytiga®) is an androgen biosynthesis inhibitor and is indicated for the treatment of prostatic neoplasms. 
• Enzalutamide (Xtandi®) is an androgen receptor inhibitor and is indicated for the treatment of prostatic neo...

Four protein kinase inhibitors now available on the interaction checker

Bosutinib, dasatinib, nilotinib and ponatinib are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications.

• Bosutinib (Bosulif®) is a protein kinase inhibitor and is indicated for the treatment of chronic myeloid leukemia (BCR-ABL positive). 
• Dasatinib (Sprycel®) is a protein kinase inhibitor and is indicated for the treat...

Four additional cancer drugs now available on the interaction checker

Imatinib, olaparib, olaratumab and regorafenib are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications.

• Imatinib (Glivec®, Gleevec®, Nibix®, Glimatin®, Imakrebin®, Leutipol®, Tilbaldix®, Mytib® ) is a protein kinase inhibitor and is indicated for the treatment of BCR-ABL positive chronic myeloid leukemia, dermatofibrosarcoma...

Lenvatinib - now available on the interaction checker

Lenvatinib is now listed in the interaction checker as a cancer drug and interactions can be found with all the comedications.

Lenvatinib (Lenvima®, Kisplyx®) is a tyrosine kinase inhibitor and is indicated for the treatment of thyroid neoplasms and renal cell carcinoma.

Temsirolimus - an new addition to the interaction checker

Temsirolimus has been added to the interaction checker as a cancer drug  and interactions are now listed with all the comedications.

Temsirolimus (Torisel^®) is a mTOR inhibitor and is indicated for the treatment of mantle-cell lymphoma and renal cell carcinoma.

Welcome to cancer-druginteractions.org

Welcome to this new website for drug interactions with anti-cancer agents. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology expertise of Radboud University Nijmegen (the Netherlands), the site will provide a world-leading DDI resource which will inform clinicians, pharmacists and patients abou...